Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Deal To Boost Progress On African Medicines Agency

Increasing Local Drug Production Is Also On The Agenda

Executive Summary

A new agreement between the WHO and the African Union is expected to strengthen efforts to create the new African Medicines Agency, following the endorsement of the AMA treaty earlier this year.

You may also be interested in...



New Alliance Urges Countries To Ratify Treaty On African Medicines Agency

Stakeholders are making a concerted effort to get the new agency off the ground, saying it will not only reduce drug approval times but help to drive industrial and economic growth in Africa. The European Medicines Agency is offering to share its experience in regulatory collaboration and network building.

African Countries Urged To Back New Medicines Agency

COVID-19 has highlighted the need for greater harmonization of medicines regulation to tackle health issues and emergencies more effectively in Africa. With that in mind, countries are being encouraged to speed up their ratification of a treaty setting up a new pan-African body tasked with coordinating national regulatory efforts, improving access to quality medicines and supporting the local pharmaceutical industry.

First Drug Approved Under New Scheme To Speed Access In Poorer Countries

Switzerland’s medicines agency has cleared Ferring’s carbetocin for preventing uterine haemorrhage under the Marketing Authorization for Global Health Products (MAGHP) procedure, which is intended to accelerate the approval of new products in low- and middle-income countries. 

Related Content

Topics

UsernamePublicRestriction

Register

PS141222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel